Series B - Engrail Therapeutics
Investment Firm
Overview
Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.
Announced Date
Mar 19, 2024
Closed on Date
Mar 19, 2024
Funding Type
Series B
Highlights
Location
United States, North America
Social
Investor Lead
Norwest Venture Partners
Norwest Venture Partners is a convertible_note and debt and early_stage_venture and late_stage_venture and private_equity and secondary_market and venture firm.
F-Prime Capital
F-Prime Capital is a early_stage_venture and late_stage_venture and seed and venture firm.
Forbion Capital Partners
Forbion Capital Partners is a early_stage_venture and post_ipo and seed firm.
Participant Investors
10
Round Details and Background
Engrail Therapeutics raised $157000000 on 2024-03-19 in Series B
Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.
Company Funding History
3
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Jun 18, 2020 |  Series A - Engrail Therapeutics | 1 | - | 32.0M |
| Aug 03, 2021 | Series A - Engrail Therapeutics | 1 | - | 32.0M |
| Mar 19, 2024 | Series B - Engrail Therapeutics | 10 | - | 157.0M |
Recent Activity
There is no recent news or activity for this profile.